Cita APA

Wermke, M., KUBOKI, Y., Sanmamed, M. F., Alese, O. B., Gambardella, V., & FELIP, E. (2025). Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.

Citación estilo Chicago

Wermke, Martin, YASUTOSHI KUBOKI, Miguel F. Sanmamed, Olatunji B. Alese, Valentina Gambardella, y ENRIQUETA FELIP. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. 2025.

Cita MLA

Wermke, Martin, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. 2025.